Clinical Trial Update: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating nivolumab for relapsed or refractory peripheral T-cell lymphoma is terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-04-21